BCM
ABMD

BBT Capital Management’s Abiomed Inc ABMD Stock Holding History

BBT Capital Management’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-789
Closed -$225K – 260
2019
Q1 		$225K Buy
+789
New +$262K 0.28% 121

Other funds holding ABMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return
AAMU
Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

BBT Capital Management's ABMD Position: Q2 2019 in Review

BBT Capital Management sold out of Abiomed Inc (ABMD) in Q2 2019, closing a stake of 789 shares — an estimated $225K sold.

BBT Capital Management first reported a position in ABMD in Q1 2019 and held it in 1 quarter. The position peaked at $225K in Q1 2019. 483 funds tracked by Wall St. Rank hold ABMD as of Q2 2019.

  • BBT Capital Management reported no remaining Abiomed Inc position as of Q2 2019 after selling out during the quarter.
  • BBT Capital Management sold 789 Abiomed Inc shares in Q2 2019, an estimated $225K.
  • BBT Capital Management first reported a position in Abiomed Inc in Q1 2019 and held it in 1 quarter.
  • BBT Capital Management's Abiomed Inc position peaked at $225K in Q1 2019.
  • 483 funds tracked by Wall St. Rank held Abiomed Inc as of Q2 2019.

Based on BBT Capital Management's 13F filing for Q2 2019, filed 9 Aug 2019.